All In Biotech

Drug Trial Radar · NCT07305831

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Jan 22, 2026

Primary completion

Apr 9, 2026

Study completion Apr 9, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.

Conditions

  • Healthy

Interventions

  • UlonivirineDrug

    Oral tablet

  • MoxifloxacinDrug

    Oral tablet

  • Ulonivirine PlaceboDrug

    Oral tablet

  • Moxifloxacin PlaceboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following Ulonivirine AdministrationTime frame: Baseline and up to approximately 24 hours
  2. Plasma Concentration of Ulonivirine at QTc Intervals (Cqtc)Time frame: At designated timepoints (up to approximately 24 hours)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services (0001)

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.